In the EU, Taiwan and Mexico, afatinib is approved for use in patients with distinct types of NSCLC under the brand name GIOTRIF®, and in the U.S. under the brand name GILOTRIF™. Afatinib is under regulatory review by health authorities in Asia and other countries.

**NON-SMALL CELL LUNG CANCER (NSCLC)**

**ADENOCARCINOMA**

**SQUAMOUS CELL CARCINOMA**

**EGFR MUTATION POSITIVE (EGFR M+)**

**TYROSINE KINASE INHIBITOR (TKI) PRETREATED**

**PIVOTAL FIRST-LINE STUDIES**

- **LUX-Lung 2 Phase II**
  - n=129
  - 30 study locations (US & Taiwan)
  - Ongoing, published

- **LUX-Lung 3 Phase III**
  - n=345
  - 134 study locations (Worldwide)
  - Ongoing, published

- **LUX-Lung 6 Phase III**
  - n=364
  - 36 study locations (China, Korea & Thailand)
  - Ongoing, reported

- **LUX-Lung 7 Phase II**
  - n=316
  - 68 study locations (Worldwide)
  - Ongoing, no longer recruiting

- **LUX-Lung 1 Phase III**
  - n=585
  - 105 study locations (Worldwide)
  - Completed, published

- **LUX-Lung 4 Phase I/II**
  - n=72
  - 20 study locations (Japan)
  - Completed, published

- **LUX-Lung 5 Phase III**
  - n=1154
  - 115 study locations (Worldwide)
  - Ongoing, no longer recruiting

- **LUX-Lung 8 Phase III**
  - n=800
  - 234 study locations (Worldwide)
  - Recruiting

**LUX-Lung Clinical Trial Programme:**

Afatinib* is being studied in a comprehensive lung cancer clinical trial programme.

*In the EU, Taiwan and Mexico, afatinib is approved for use in patients with distinct types of NSCLC under the brand name GIOTRIF®, and in the U.S. under the brand name GILOTRIF™. Afatinib is under regulatory review by health authorities in Asia and other countries.

© 2012 Boehringer Ingelheim GmbH. All rights reserved | Last updated: August 2013